Clinically and orally compatible formulation-manufactured DDX5 (p68)-targeting molecular glue FL118 products exhibit low toxicity but high efficacy against human cancer
Saved in:
| Main Authors: | Xiang Ling, Wenjie Wu, Li Yan, Leslie Curtin, Melanie M. Farrauto, Sandra Sexton, Anmbreen Jamroze, Changjun Yu, Christos Fountzilas, Dean G. Tang, Fengzhi Li |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-11-01
|
| Series: | Journal of Pharmaceutical Analysis |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2095177924000984 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Introducción 117-118
by: Revista Controversia
Published: (1983-12-01) -
Glueing of Fundal Varices
by: Nasim Mahmoudi, et al.
Published: (2006-01-01) -
DAPK enhances DDX20 protein stability via suppression of TRIM25-mediated ubiquitination-based DDX20 degradation
by: Yan Ye, et al.
Published: (2024-11-01) -
Molecular glue degrader for tumor treatment
by: Yuhan Hu, et al.
Published: (2024-12-01) -
Targeting active RAS with molecular glue
by: Wenjing Su, et al.
Published: (2024-12-01)